Connection

GREG CUNY to Humans

This is a "connection" page, showing publications GREG CUNY has written about Humans.
Connection Strength

0.517
  1. Pyridopyrimidinones as a new chemotype of calcium dependent protein kinase 1 (CDPK1) inhibitors for Cryptosporidium. Mol Biochem Parasitol. 2024 12; 260:111637.
    View in: PubMed
    Score: 0.025
  2. Structure-activity relationship of BMS906024 derivatives for Cryptosporidium parvum growth inhibition. Bioorg Med Chem Lett. 2023 06 15; 90:129328.
    View in: PubMed
    Score: 0.024
  3. Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling. Eur J Med Chem. 2021 Apr 05; 215:113252.
    View in: PubMed
    Score: 0.020
  4. Mycophenolic anilides as broad specificity inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors. Bioorg Med Chem Lett. 2020 12 15; 30(24):127543.
    View in: PubMed
    Score: 0.020
  5. RIPK protein kinase family: Atypical lives of typical kinases. Semin Cell Dev Biol. 2021 01; 109:96-105.
    View in: PubMed
    Score: 0.019
  6. Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold. Eur J Med Chem. 2020 Aug 15; 200:112417.
    View in: PubMed
    Score: 0.019
  7. Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors. Bioorg Med Chem Lett. 2018 02 15; 28(4):577-583.
    View in: PubMed
    Score: 0.016
  8. Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016). Expert Opin Ther Pat. 2017 Jun; 27(6):677-690.
    View in: PubMed
    Score: 0.015
  9. Divergent Approach for the Synthesis of Gombamide A and Derivatives. Org Lett. 2016 09 16; 18(18):4726-9.
    View in: PubMed
    Score: 0.015
  10. Synthesis and Antiproliferative Activity Evaluation of the Disulfide-Containing Cyclic Peptide Thiochondrilline C and Derivatives. J Nat Prod. 2015 Oct 23; 78(10):2398-404.
    View in: PubMed
    Score: 0.014
  11. Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking. Bioorg Med Chem Lett. 2015 Jul 01; 25(13):2713-9.
    View in: PubMed
    Score: 0.013
  12. Optimization of benzoxazole-based inhibitors of Cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem. 2013 May 23; 56(10):4028-43.
    View in: PubMed
    Score: 0.012
  13. Selective and potent urea inhibitors of cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem. 2012 Sep 13; 55(17):7759-71.
    View in: PubMed
    Score: 0.011
  14. Foreword: neurodegenerative diseases: challenges and opportunities. Future Med Chem. 2012 Sep; 4(13):1647-9.
    View in: PubMed
    Score: 0.011
  15. Optimization of tricyclic Nec-3 necroptosis inhibitors for in vitro liver microsomal stability. Bioorg Med Chem Lett. 2012 Sep 01; 22(17):5685-8.
    View in: PubMed
    Score: 0.011
  16. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors. Bioorg Med Chem Lett. 2012 Mar 01; 22(5):2015-9.
    View in: PubMed
    Score: 0.011
  17. Structure-activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH. Bioorg Med Chem Lett. 2012 Mar 01; 22(5):1985-8.
    View in: PubMed
    Score: 0.011
  18. Synthesis of fused imidazoles, pyrroles, and indoles with a defined stereocenter a to nitrogen utilizing Mitsunobu alkylation followed by palladium-catalyzed cyclization. J Org Chem. 2011 Oct 21; 76(20):8477-82.
    View in: PubMed
    Score: 0.011
  19. Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15; 20(12):3491-4.
    View in: PubMed
    Score: 0.010
  20. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009 Nov 01; 19(21):6122-6.
    View in: PubMed
    Score: 0.009
  21. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466. Expert Opin Ther Pat. 2009 Jun; 19(6):893-9.
    View in: PubMed
    Score: 0.009
  22. Structure-activity relationship and liver microsome stability studies of pyrrole necroptosis inhibitors. Bioorg Med Chem Lett. 2008 Jun 01; 18(11):3219-23.
    View in: PubMed
    Score: 0.008
  23. Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors. Bioorg Med Chem Lett. 2007 Dec 15; 17(24):6836-40.
    View in: PubMed
    Score: 0.008
  24. Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors. Bioorg Med Chem Lett. 2007 Jul 01; 17(13):3729-32.
    View in: PubMed
    Score: 0.008
  25. Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem. 2007 Apr 19; 50(8):1886-95.
    View in: PubMed
    Score: 0.008
  26. Effects of a verbenachalcone derivative on neurite outgrowth, inhibition of caspase induction and gene expression. Bioorg Med Chem Lett. 2005 Feb 15; 15(4):1193-6.
    View in: PubMed
    Score: 0.007
  27. Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorg Med Chem Lett. 2004 Sep 06; 14(17):4379-82.
    View in: PubMed
    Score: 0.006
  28. Necroptosis blockade prevents lung injury in severe influenza. Nature. 2024 Apr; 628(8009):835-843.
    View in: PubMed
    Score: 0.006
  29. A small molecule exerts selective antiviral activity by targeting the human cytomegalovirus nuclear egress complex. PLoS Pathog. 2023 Nov; 19(11):e1011781.
    View in: PubMed
    Score: 0.006
  30. Nonhydrolyzable d-phenylalanine-benzoxazole derivatives retain antitubercular activity. Bioorg Med Chem Lett. 2023 01 15; 80:129116.
    View in: PubMed
    Score: 0.006
  31. Development of Rofecoxib-Based Fluorescent Probes and Investigations on Their Solvatochromism, AIE Activity, Mechanochromism, and COX-2-Targeted Bioimaging. Anal Chem. 2021 09 07; 93(35):11991-12000.
    View in: PubMed
    Score: 0.005
  32. Targeted Degradation of the Oncogenic Phosphatase SHP2. Biochemistry. 2021 08 31; 60(34):2593-2609.
    View in: PubMed
    Score: 0.005
  33. Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor. Cell Death Dis. 2021 07 14; 12(7):699.
    View in: PubMed
    Score: 0.005
  34. One-Step Transformation from Rofecoxib to a COX-2 NIR Probe for Human Cancer Tissue/Organoid Targeted Bioimaging. ACS Appl Bio Mater. 2021 03 15; 4(3):2723-2731.
    View in: PubMed
    Score: 0.005
  35. Genetic ablation of purine salvage in Cryptosporidium parvum reveals nucleotide uptake from the host cell. Proc Natl Acad Sci U S A. 2019 10 15; 116(42):21160-21165.
    View in: PubMed
    Score: 0.005
  36. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett. 2018 11 01; 28(20):3356-3362.
    View in: PubMed
    Score: 0.004
  37. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling. EMBO J. 2018 09 03; 37(17).
    View in: PubMed
    Score: 0.004
  38. Expanding Benzoxazole-Based Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure-Activity As Potential Antituberculosis Agents. J Med Chem. 2018 06 14; 61(11):4739-4756.
    View in: PubMed
    Score: 0.004
  39. Optimization of a series of heterocycles as survival motor neuron gene transcription enhancers. Bioorg Med Chem Lett. 2017 12 01; 27(23):5144-5148.
    View in: PubMed
    Score: 0.004
  40. Benzoxazoles, Phthalazinones, and Arylurea-Based Compounds with IMP Dehydrogenase-Independent Antibacterial Activity against Francisella tularensis. Antimicrob Agents Chemother. 2017 10; 61(10).
    View in: PubMed
    Score: 0.004
  41. Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy. J Med Chem. 2017 06 08; 60(11):4594-4610.
    View in: PubMed
    Score: 0.004
  42. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors. Chem Biol. 2015 Sep 17; 22(9):1174-84.
    View in: PubMed
    Score: 0.003
  43. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Rep. 2015 Mar 24; 10(11):1850-60.
    View in: PubMed
    Score: 0.003
  44. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 09; 57(19):7900-15.
    View in: PubMed
    Score: 0.003
  45. Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease. PLoS Biol. 2014 Aug; 12(8):e1001923.
    View in: PubMed
    Score: 0.003
  46. Enzymatic Characterization of ER Stress-Dependent Kinase, PERK, and Development of a High-Throughput Assay for Identification of PERK Inhibitors. J Biomol Screen. 2014 Aug; 19(7):1024-34.
    View in: PubMed
    Score: 0.003
  47. Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. Antimicrob Agents Chemother. 2014; 58(3):1603-14.
    View in: PubMed
    Score: 0.003
  48. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther. 2013 Dec; 12(12):2651-62.
    View in: PubMed
    Score: 0.003
  49. Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO Mol Med. 2013 Jul; 5(7):1103-18.
    View in: PubMed
    Score: 0.003
  50. Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models. J Biol Chem. 2013 Jul 26; 288(30):22042-56.
    View in: PubMed
    Score: 0.003
  51. Development of an ALK2-biased BMP type I receptor kinase inhibitor. ACS Chem Biol. 2013; 8(6):1291-302.
    View in: PubMed
    Score: 0.003
  52. A new class of small molecule inhibitor of BMP signaling. PLoS One. 2013; 8(4):e62721.
    View in: PubMed
    Score: 0.003
  53. Expression and purification of active receptor interacting protein 1 kinase using a baculovirus system. Protein Expr Purif. 2013 Jun; 89(2):156-61.
    View in: PubMed
    Score: 0.003
  54. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S. Biochemistry. 2013 Mar 12; 52(10):1725-36.
    View in: PubMed
    Score: 0.003
  55. Phthalazinone inhibitors of inosine-5'-monophosphate dehydrogenase from Cryptosporidium parvum. Bioorg Med Chem Lett. 2013 Feb 15; 23(4):1004-7.
    View in: PubMed
    Score: 0.003
  56. Small-molecule Klotho enhancers as novel treatment of neurodegeneration. Future Med Chem. 2012 Sep; 4(13):1671-9.
    View in: PubMed
    Score: 0.003
  57. Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases. Future Med Chem. 2012 Sep; 4(13):1689-700.
    View in: PubMed
    Score: 0.003
  58. A high-throughput screen to identify inhibitors of SOD1 transcription. Front Biosci (Elite Ed). 2012 06 01; 4(8):2701-8.
    View in: PubMed
    Score: 0.003
  59. Fluorescence polarization assay for inhibitors of the kinase domain of receptor interacting protein 1. Anal Biochem. 2012 Aug 15; 427(2):164-74.
    View in: PubMed
    Score: 0.003
  60. Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease. Antiviral Res. 2012 Apr; 94(1):18-24.
    View in: PubMed
    Score: 0.003
  61. Identification of novel compounds that increase SMN protein levels using an improved SMN2 reporter cell assay. J Biomol Screen. 2012 Apr; 17(4):481-95.
    View in: PubMed
    Score: 0.003
  62. Development of a high-throughput screen targeting caspase-8-mediated cleavage of the amyloid precursor protein. Anal Biochem. 2012 Feb 15; 421(2):467-76.
    View in: PubMed
    Score: 0.003
  63. Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry. 2011 Nov 01; 50(43):9399-408.
    View in: PubMed
    Score: 0.003
  64. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood. 2011 May 05; 117(18):4915-23.
    View in: PubMed
    Score: 0.003
  65. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell. 2010 Oct 19; 18(4):382-95.
    View in: PubMed
    Score: 0.002
  66. Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors. Anal Biochem. 2010 Sep 15; 404(2):186-92.
    View in: PubMed
    Score: 0.002
  67. Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity. J Biomol Screen. 2010 Jul; 15(6):653-62.
    View in: PubMed
    Score: 0.002
  68. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One. 2010 May 07; 5(5):e10504.
    View in: PubMed
    Score: 0.002
  69. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. J Med Chem. 2010 Apr 08; 53(7):2709-18.
    View in: PubMed
    Score: 0.002
  70. The structural basis of Cryptosporidium -specific IMP dehydrogenase inhibitor selectivity. J Am Chem Soc. 2010 Feb 03; 132(4):1230-1.
    View in: PubMed
    Score: 0.002
  71. Identification of small molecule inhibitors of the mitotic kinase haspin by high-throughput screening using a homogeneous time-resolved fluorescence resonance energy transfer assay. J Biomol Screen. 2008 Dec; 13(10):1025-34.
    View in: PubMed
    Score: 0.002
  72. Small-molecule inhibitors of phosphatidylcholine transfer protein/StarD2 identified by high-throughput screening. Anal Biochem. 2008 Dec 01; 383(1):85-92.
    View in: PubMed
    Score: 0.002
  73. Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors. Biochemistry. 2008 Aug 12; 47(32):8367-77.
    View in: PubMed
    Score: 0.002
  74. Small molecules that enhance the catalytic efficiency of HLA-DM. J Immunol. 2006 Apr 01; 176(7):4208-20.
    View in: PubMed
    Score: 0.002
  75. Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett. 2005 Nov 15; 15(22):5039-44.
    View in: PubMed
    Score: 0.002
  76. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005 Jul; 1(2):112-9.
    View in: PubMed
    Score: 0.002
  77. FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J Mol Neurosci. 2004; 24(1):129-36.
    View in: PubMed
    Score: 0.002
  78. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol. 2003 Sep; 10(9):837-46.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.